[From drug evaluation to that of a path: the challenges for regulatory authorities]

Abstract

To understand how the current organization of the drug evaluation leads to a compartmental vision, and what tools could be added to bring the regulatory activity closer to the goal of include the entire therapeutic path. This is an hard goal but, if we overcome the compartmental approach and open up to tools useful for planning and managing the intervention, the drug evaluation process could come to include the entire therapeutic path.